These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16955532)

  • 1. Everolimus drug interactions: application of a classification system for clinical decision making.
    Kovarik JM; Beyer D; Schmouder RL
    Biopharm Drug Dispos; 2006 Dec; 27(9):421-6. PubMed ID: 16955532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.
    Kovarik JM; Beyer D; Bizot MN; Jiang Q; Allison MJ; Schmouder RL
    Br J Clin Pharmacol; 2005 Oct; 60(4):434-7. PubMed ID: 16187976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood concentrations of everolimus are markedly increased by ketoconazole.
    Kovarik JM; Beyer D; Bizot MN; Jiang Q; Shenouda M; Schmouder RL
    J Clin Pharmacol; 2005 May; 45(5):514-8. PubMed ID: 15831774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of multiple-dose erythromycin on everolimus pharmacokinetics.
    Kovarik JM; Beyer D; Bizot MN; Jiang Q; Shenouda M; Schmouder RL
    Eur J Clin Pharmacol; 2005 Mar; 61(1):35-8. PubMed ID: 15785960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
    Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
    Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction.
    Kovarik JM; Kalbag J; Figueiredo J; Rouilly M; Frazier OL; Rordorf C
    J Clin Pharmacol; 2002 Jan; 42(1):95-9. PubMed ID: 11808830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
    Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
    J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rifampin on apparent clearance of everolimus.
    Kovarik JM; Hartmann S; Figueiredo J; Rouilly M; Port A; Rordorf C
    Ann Pharmacother; 2002 Jun; 36(6):981-5. PubMed ID: 12022896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.
    Kovarik JM; Bartlett M; Rordorf C; Antunes MC; Winter S; Marbach P; van Marle S
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):103-8. PubMed ID: 20137762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
    Han B; Mao J; Chien JY; Hall SD
    Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.
    Brandhorst G; Tenderich G; Zittermann A; Oezpeker C; Koerfer R; Oellerich M; Armstrong VW
    Ther Drug Monit; 2008 Feb; 30(1):113-6. PubMed ID: 18223473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
    Zhao P; Ragueneau-Majlessi I; Zhang L; Strong JM; Reynolds KS; Levy RH; Thummel KE; Huang SM
    J Clin Pharmacol; 2009 Mar; 49(3):351-9. PubMed ID: 19246732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.
    Kovarik JM; Hartmann S; Figueiredo J; Rordorf C; Golor G; Lison A; Budde K; Neumayer HH
    Pharmacotherapy; 2002 Feb; 22(2):154-9. PubMed ID: 11837553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
    Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
    Drug Metab Dispos; 2011 Apr; 39(4):591-602. PubMed ID: 21212240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats.
    Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
    Biopharm Drug Dispos; 2009 Dec; 30(9):517-23. PubMed ID: 19790241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.